LSLucy A. M. Simmons

Lucy A. M. Simmons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lucy A. M. Simmons has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline M. Moore

    Division of Surgery and Interventional Science, University College London, Faculty of Medical Sciences, London, UK

    4 shared publications
  • Mark Emberton

    Division of Surgery and Interventional Science, University College London, Faculty of Medical Sciences, London, UK

    4 shared publications
  • Alex Freeman

    Department of Pathology, UCLH NHS Foundation Trust, London, UK

    2 shared publications
  • Arnauld Villers

    Department of Urology, Lille University Hospital, 59000 Lille, France

    2 shared publications
  • Dean Barratt

    Centre for Medical Image Computing, University College London, London, UK

    2 shared publications
  • Dror Nir

    Department of Electrical Engineering, Imperial College of Science, Technology and Medicine, London, UK

    2 shared publications

Latest Publications

  • Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning

    by Lucy A. M. Simmons, Abi Kanthabalan, Manit Arya, Tim Briggs, Susan C. Charman, Alex Freeman, James Gelister, Charles Jameson, Neil McCartan, Caroline M. Moore, et al.

    Men with negative prostate biopsies or those diagnosed with low-risk or low-volume intermediate-risk prostate cancers often require a second prostate biopsy prior to a treatment decision. Prostate HistoScanning (PHS) is an ultrasound imaging test that might inform prostate biopsy in such men. PICTURE was a prospective, paired-cohort validating trial to assess the diagnostic accuracy of imaging in men requiring a further biopsy (clinicaltrials.gov, NCT01492270) (11 January 2012–29 January 2014). We enrolled 330 men who had undergone a prior TRUS biopsy but where diagnostic uncertainty remained. All eligible men underwent PHS and transperineal template prostate mapping (TTPM) biopsy (reference standard). Men were blinded to the imaging results until after undergoing TTPM biopsies. We primarily assessed the ability of PHS to rule out clinically significant prostate (negative predictive value [NPV] and sensitivity) for a target histological condition of Gleason ≥4+3 and/or a cancer core length (MCCL) ≥6 mm. We also assessed the role of visually estimated PHS-targeted biopsies. Of the 330 men enrolled, 249 underwent both PHS and TTPM biopsy. Mean (SD) age was 62 (7) years, median (IQR) PSA 6.8 (4.98–9.50) ng/ml, median (IQR) number of previous biopsies 1 (1–2) and mean (SD) gland size 37 (15.5) ml. One hundred and forty six (59%) had no clinically significant cancer. PHS classified 174 (70%) as suspicious. Sensitivity was 70.3% (95% CI 59.8–79.5) and NPV 41.3% (95% CI 27.0–56.8). Specificity and positive predictive value (PPV) were 14.7% (95% CI 9.1–22.0) and 36.8% (95% CI 29.6–44.4), respectively. In all, 213/220 had PHS suspicious areas targeted with targeting sensitivity 13.6% (95% CI 7.3–22.6), specificity 97.6% (95% CI 93.1–99.5), NPV 61.6% (95% CI 54.5–68.4) and PPV 80.0% (95% CI 51.9–95.7). PHS is not a useful test in men seeking risk stratification following initial prostate biopsy.


  • Open Access

    Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI

    by Mrishta Brizmohun Appayya, Harbir S Sidhu, Nikolaos Dikaios, Edward W Johnston, Lucy Am Simmons, Alex Freeman, Alexander Ps Kirkham, Hashim U Ahmed, Shonit Punwani

    Objective: To determine whether indeterminate (Likert-score 3/5) peripheral zone (PZ) multiparametric MRI (mpMRI) studies are classifiable by prostate-specific antigen (PSA), PSA density (PSAD), Prostate Imaging Reporting And Data System version 2 (PI-RADS_v2) rescoring and morphological MRI features. Methods: Men with maximum Likert-score 3/5 within their PZ were retrospectively selected from 330 patients who prospectively underwent prostate mpMRI (3 T) without an endorectal coil, followed by 20-zone transperineal template prostate mapping biopsies +/- focal lesion-targeted biopsy. PSAD was calculated using pre-biopsy PSA and MRI-derived volume. Two readers A and B independently assessed included men with both Likert-assessment and PI-RADS_v2. Both readers then classified mpMRI morphological features in consensus. Men were divided into two groups: significant cancer (≥ Gleason 3 + 4) or insignificant cancer (≤ Gleason 3 + 3)/no cancer. Comparisons between groups were made separately for PSA & PSAD using Mann–Whitney test and morphological descriptors with Fisher’s exact test. PI-RADS_v2 and Likert-assessment were descriptively compared and percentage inter-reader agreement calculated. Results: 76 males were eligible for PSA & PSAD analyses, 71 for PI-RADS scoring, and 67 for morphological assessment (excluding significant image artefacts). Unlike PSA (p = 0.915), PSAD was statistically different (p = 0.004) between the significant [median: 0.19 ng ml– 2 (interquartile range: 0.13–0.29)] and non-significant/no cancer [median: 0.13 ng ml– 2 (interquartile range: 0.10–0.17)] groups. Presence of mpMRI morphological features was not significantly different between groups. Subjective Likert-assessment discriminated patients with significant cancer better than PI-RADS_v2. Inter-reader percentage agreement was 83% for subjective Likert-assessment and 56% for PI-RADS_v2. Conclusion: PSAD may categorize presence of significant cancer in patients with Likert-scored 3/5 PZ mpMRI findings. Advances in knowledge: PSAD may be used in indeterminate PZ mpMRI to guide decisions between biopsy vs monitoring.


  • Open Access

    Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy

    by Yipeng Hu, Veeru Kasivisvanathan, Lucy A. M. Simmons, Matthew J. Clarkson, Stephen A. Thompson, Taimur T. Shah, Hashim U. Ahmed, Shonit Punwani, David J. Hawkes, Mark Emberton, et al.

    Objective: Three- and four-dimensional transrectal ultrasound transducers are now available from most major ultrasound equipment manufacturers, but currently are incorporated into only one commercial prostate biopsy guidance system. Such transducers offer the benefits of rapid volumetric imaging, but can cause substantial measurement distortion in electromagnetic tracking sensors, which are commonly used to enable 3-D navigation. In this paper, we describe the design, development, and validation of a 3-D-ultrasound-guided transrectal prostate biopsy system that employs high-accuracy optical tracking to localize the ultrasound probe and prostate targets in 3-D physical space. Methods: The accuracy of the system was validated by evaluating the targeted needle placement error after inserting a biopsy needle to sample planned targets in a phantom using standard 2-D ultrasound guidance versus real-time 3-D guidance provided by the new system. Results: The overall mean needle-segment-to-target distance error was 3.6 ± 4.0 mm and mean needle-to-target distance was 3.2 ± 2.4 mm. Conclusion: A significant increase in needle placement accuracy was observed when using the 3-D guidance system compared with visual targeting of invisible (virtual) lesions using a standard B-mode ultrasound-guided biopsy technique.


  • Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design

    by Willemien van Den Bos, Berrend G. Muller, Daniel M. de Bruin, Andre Luis de Castro Abreu, Christian Chaussy, Jonathan A. Coleman, Antonio Finelli, Inderbir S. Gill, Mitchell E. Gross, Sjoerd F.M. Jenniskens, et al.


  • Top Cited Papers
    Open Access

    Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting

    by Ian A. Donaldson, Roberto Alonzi, Dean Barratt, Eric Barret, Viktor Berge, Simon Bott, David Bottomley, Scott Eggener, Behfar Ehdaie, Mark Emberton, et al.


  • Using imaging biomarkers to improve the planning of radical prostatectomies

    by Nicholas A. Faure Walker, Dror Nir, Lucy Simmons, Sachin Agrawal, Christopher Chung, Artur Leminski, Tina Rashid, Altaf Shamsuddin, Mathias Winkler


  • The PICTURE study — Prostate Imaging (multi-parametric MRI and Prostate HistoScanning™) Compared to Transperineal Ultrasound guided biopsy for significant prostate cancer Risk Evaluation

    by Lucy A.M. Simmons, Hashim Uddin Ahmed, Caroline M. Moore, Shonit Punwani, Alex Freeman, Yipeng Hu, Dean Barratt, Susan C. Charman, Jan Van der Meulen, Mark Emberton


  • Open Access

    Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning ™

    by Lucy A.M. Simmons, Philippe Autier, Frantiŝek Zát'Ura, Johan Braeckman, Alexandre Peltier, Imre Romic, Arnulf Stenzl, Karien Treurnicht, Tara Walker, Dror Nir, et al.

    What's known on the subject? and What does the study add? Prostate cancer is one of the few solid‐organ cancers in which imaging is not used in the diagnostic process. Novel functional magnetic resonance imaging techniques offer promise but may not be cost‐effective. Prostate HistoScanning ™ (PHS) is an ultrasound‐based tissue characterisation technique that has previously shown encouraging results in the detection of clinically significant prostate cancer. The present study reports on the open ‘unblinded’ phase of a European multicentre study. The prospective ‘blind’ phase is currently in progress and will determine the value of PHS in a robust fashion overcoming many of the biases inherent in evaluating prostate imaging. OBJECTIVE: To evaluate the ability of prostate HistoScanning ™ (PHS) an ultrasound (US)‐based tissue characterization application, to detect cancer foci by correlating results with detailed radical prostatectomy (RP) histology. PATIENT AND METHODS: In all, 31 patients with organ‐confined prostate cancer, diagnosed on transrectal biopsies taken using US guidance, and scheduled for RP were recruited from six European centres. Before RP three‐dimensional (3D) US raw data for PHS analysis was obtained. Histology by Bostwick Laboratories (London) examined sections obtained from whole mounted glands cut every 3–4 mm. Location and volume estimation of cancer foci by PHS were undertaken using two methods; a manual method and an embedded software tool. In this report we evaluate data obtained from a planned open study phase. The second phase of the study is ‘blinded’, and currently in progress. RESULTS: 31 patients were eligible for this phase. Three patients were excluded from analysis due to inadequate scan acquisition and pathology violations of the standard operating procedure. One patient withdrew from the study after 3D TRUS examination. PHS detected cancer ≥0.20 mL in 25/27 prostates (sensitivity 93%). In all, 23 patients had an index focus ≥0.5 mL at pathology, of which 21 were identified as ≥0.5 mL by PHS using the manual method (sensitivity 91%) and 19 were correctly identified as ≥0.5 mL by the embedded tool (sensitivity 83%). In 27 patients, histological analysis found 32 cancerous foci ≥0.2 mL, located in 97 of 162 sextants. After sextant analysis, PHS showed a 90% sensitivity and 72% specificity for the localisation of lesions ≥0.2 mL within a sextant. CONCLUSIONS: PHS has the ability to identify and locate prostate cancer and consequently may aid in pre‐treatment and pre‐surgical planning. In men with a lesion identified, it has potential to enable improved targeting, allowing better risk stratification by obtaining more representative cores. However further verification from the results of the blinded phase of this study are awaited.